胱氨酸摄取抑制增强急性髓系白血病的一线治疗
研究通过多组AML数据集锁定xCT胱氨酸转运体SLC7A11为潜在依赖靶点,遗传和化学抑制SLC7A11以胱氨酸依赖方式损害AML细胞系活力和克隆形成能力。柳氮磺吡啶在体外对原代AML样本有抗白血病活性,与柔红霉素联用协同,在45例富集NPM1突变AML原代样本中显著增强柔红霉素-阿糖胞苷方案活性,并在患者来源异种移植模型中证实。
要点
- SLC7A11编码的xCT胱氨酸转运体被鉴定为AML的潜在依赖靶点。
- 柳氮磺吡啶在体外对原代AML样本有抗白血病活性,与柔红霉素协同最强。
- 柳氮磺吡啶在临床相关浓度下增强柔红霉素-阿糖胞苷对45例原代样本的活性。
核心结论
- 胱氨酸摄取是AML的可成药靶点,柳氮磺吡啶有望老药新用治疗AML,尤其与化疗联合。
研究设计与样本
- 研究通过查询多个AML数据集中与白血病干性和生存相关的代谢通路,锁定SLC7A11为候选AML依赖靶点。
- 采用遗传和化学抑制SLC7A11,在AML细胞系、原代AML样本体外培养及患者来源异种移植模型中进行验证。
主要发现
- 遗传和化学抑制SLC7A11以胱氨酸依赖方式损害AML细胞系活力和克隆形成能力。
- 柳氮磺吡啶在体外对原代AML样本有抗白血病活性,xCT抑制影响多条代谢通路,耗竭白血病细胞谷胱甘肽池并导致氧化应激依赖性细胞死亡,仅部分通过铁死亡。
- NPM1突变AML中半胱氨酸代谢基因表达更高且胱氨酸依赖性更强。
- 在八种抗白血病药物中,蒽环类柔红霉素被鉴定为体外与柳氮磺吡啶联用协同作用最强的药物。
- 在45例富集NPM1突变AML的原代样本中,临床相关浓度柳氮磺吡啶显著增强柔红霉素-阿糖胞苷联合方案的抗白血病活性,并在患者来源异种移植模型中证实。
临床怎么用
- 作者提出胱氨酸输入是AML的可成药靶点,并提出柳氮磺吡啶老药新用于AML治疗的可能性,尤其与化疗联合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
By querying metabolic pathways associated with leukemic stemness and survival in multiple AML datasets, we nominated SLC7A11 encoding the xCT cystine importer as a putative AML dependency. Genetic and chemical inhibition of SLC7A11 impaired the viability and clonogenic capacity of AML cell lines in a cysteine-dependent manner. Sulfasalazine, a broadly available drug with xCT inhibitory activity, had anti-leukemic activity against primary AML samples in ex vivo cultures. Multiple metabolic pathways were impacted upon xCT inhibition, resulting in depletion of glutathione pools in leukemic cells and oxidative stress-dependent cell death, only in part through ferroptosis. Higher expression of cysteine metabolism genes and greater cystine dependency was noted in NPM1-mutated AMLs. Among eight anti-leukemic drugs, the anthracycline daunorubicin was identified as the top synergistic agent in combination with sulfasalazine in vitro. Addition of sulfasalazine at a clinically relevant concentration significantly augmented the anti-leukemic activity of a daunorubicin-cytarabine combination in a panel of 45 primary samples enriched in NPM1-mutated AML. These results were confirmed in vivo in a patient-derived xenograft model. Collectively, our results nominate cystine import as a druggable target in AML and raise the possibility to repurpose sulfasalazine for the treatment of AML, notably in combination with chemotherapy.
引用
- Pardieu B, Pasanisi J, Ling F, et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia. 2022. PMID: 35474100. doi:10.1038/s41375-022-01573-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。